Related references
Note: Only part of the references are listed.FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini et al.
NATURE (2023)
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani et al.
NATURE (2023)
Development of Highly Potent Noncovalent Inhibitors of SARS- CoV-2 3CLpro
Ningke Hou et al.
ACS CENTRAL SCIENCE (2023)
4′-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives
Junbiao Chang
ACCOUNTS OF CHEMICAL RESEARCH (2022)
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
Daniele Focosi et al.
ANTIVIRAL RESEARCH (2022)
Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
Pengcheng Han et al.
CELL (2022)
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Zhen Cui et al.
CELL (2022)
Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2
Shaojun Zhang et al.
CELL RESEARCH (2022)
In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery
Zhonglei Wang et al.
JOURNAL OF MEDICAL VIROLOGY (2022)
Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L
Anneliese S. Ashhurst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses
Andreas Luttens et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Kang Wang et al.
NATURE (2022)
Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design
Brandon Malone et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)
Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
R. L. Gottlieb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody
Wanchao Yin et al.
SCIENCE (2022)
Computationally driven discovery of SARS-CoV-2 Mpro inhibitors: from design to experimental validation
Lea El Khoury et al.
CHEMICAL SCIENCE (2022)
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay
Wenyue Cao et al.
ACS CENTRAL SCIENCE (2022)
Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors
Gustavo R. Perez-Lemus et al.
SCIENCE ADVANCES (2022)
Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2
Wenhao Dai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
Naoya Kitamura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
Hong-jie Qian et al.
ACTA PHARMACOLOGICA SINICA (2022)
Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis
Martin Sachse et al.
ANTIVIRAL RESEARCH (2022)
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
Cheng Li et al.
CELL (2022)
Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations
Anita Kumari et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
Bing Bai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
Florence Ader et al.
LANCET INFECTIOUS DISEASES (2022)
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CLProtease Inhibitor Clinical Candidate for Treating COVID-19
Yuto Unoh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
Rafael Dal-Re et al.
LANCET INFECTIOUS DISEASES (2022)
Molecular basis of receptor binding and antibody neutralization of Omicron
Qin Hong et al.
NATURE (2022)
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Tongqing Zhou et al.
SCIENCE (2022)
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Shiv Gandhi et al.
NATURE COMMUNICATIONS (2022)
Paxlovid™ Information From US Food & Drug Administration (FDA) and Guidance for AES Members
Jon A. Cokley et al.
EPILEPSY CURRENTS (2022)
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
Yinzhong Shen et al.
EMERGING MICROBES & INFECTIONS (2022)
The future of Paxlovid for COVID-19
Talha Burki
LANCET RESPIRATORY MEDICINE (2022)
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Bao-Xue Quan et al.
NATURE MICROBIOLOGY (2022)
Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19
Henrik Berg Rasmussen et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2
Wenying Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1
Linjie Li et al.
CELL (2022)
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Sho Iketani et al.
CELL HOST & MICROBE (2022)
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Yuyong Zhou et al.
SCIENCE ADVANCES (2022)
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao et al.
NATURE (2022)
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
Weijuan Shang et al.
ANTIVIRAL RESEARCH (2022)
A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors
Liming Yan et al.
CELL (2022)
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Carlos K H Wong et al.
LANCET (2022)
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal et al.
EBIOMEDICINE (2022)
SARS-CoV-2 Main Protease Drug Design, Assay Development, and Resistance Studies
Bin Tan et al.
ACCOUNTS OF CHEMICAL RESEARCH (2022)
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment
Irine Pauly et al.
CURRENT PHARMACEUTICAL DESIGN (2022)
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity
Shenghua Gao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
Rune M. Pedersen et al.
EMERGING INFECTIOUS DISEASES (2022)
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease
Yuya Hirose et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Development of Ultrapure and Potent Tannic Acids as a Pan-coronal Antiviral Therapeutic
Po-Chang Shih et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
LANCET (2022)
RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target
Yanyan Wang et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus
Shasha Li et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription Complex Reveals an Intermediate State in Cap Synthesis
Liming Yan et al.
CELL (2021)
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
Yuanchao Xie et al.
CELL RESEARCH (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Ivan O. Rosas et al.
INTENSIVE CARE MEDICINE (2021)
Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
Anjum S. Kaka et al.
ANNALS OF INTERNAL MEDICINE (2021)
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
Chunlong Ma et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Antiviral Bafilomycins from a Feces-Inhabiting Streptomyces sp.
Xi Xie et al.
JOURNAL OF NATURAL PRODUCTS (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Kris M. White et al.
SCIENCE (2021)
SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model
Jingxin Qiao et al.
SCIENCE (2021)
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Britton Boras et al.
NATURE COMMUNICATIONS (2021)
Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants
Pengcheng Han et al.
NATURE COMMUNICATIONS (2021)
Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations
Chun-Hui Zhang et al.
ACS CENTRAL SCIENCE (2021)
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
Sebastian Guenther et al.
SCIENCE (2021)
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment
Jiashu Xie et al.
ACTA PHARMACEUTICA SINICA B (2021)
Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses
Hong Zhou et al.
CELL (2021)
Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading
Liming Yan et al.
CELL (2021)
Drug metabolic stability in early drug discovery to develop potential lead compounds
Siva Nageswara Rao Gajula et al.
DRUG METABOLISM REVIEWS (2021)
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
Luis Menendez-Arias
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease
Chamandi S. Dampalla et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Florian Kabinger et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)
Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets
Nunziata Maio et al.
SCIENCE (2021)
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Nir Drayman et al.
SCIENCE (2021)
SARS-CoV-2: from its discovery to genome structure, transcription, and replication
Ayslan Castro Brant et al.
CELL AND BIOSCIENCE (2021)
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
Liyan Yang et al.
BIOMEDICINES (2021)
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
Jin-Lan Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
Zhonglei Wang et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
Zilei Xia et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis
Guo-Fu Li et al.
GUT (2021)
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Miao-Miao Zhao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products
Chang-Long He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses
Na Xu et al.
JOURNAL OF VIROLOGY (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Renhong Yan et al.
SCIENCE (2020)
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase
Quan Wang et al.
CELL (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
Hua-Hao Fan et al.
CHINESE MEDICAL JOURNAL (2020)
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Wenhao Dai et al.
SCIENCE (2020)
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Yan Gao et al.
SCIENCE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Wanchao Yin et al.
SCIENCE (2020)
Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2
Qi Peng et al.
CELL REPORTS (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Structure of replicating SARS-CoV-2 polymerase
Hauke S. Hillen et al.
NATURE (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins
Tommy Tsan-Yuk Lam et al.
NATURE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Chunlong Ma et al.
CELL RESEARCH (2020)
A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study
Zhigang Ren et al.
ADVANCED SCIENCE (2020)
Mechanistic Insight into Antiretroviral Potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention
Li Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular Architecture of the SARS-CoV-2 Virus
Hangping Yao et al.
CELL (2020)
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
Donghyuk Shin et al.
NATURE (2020)
Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
Yanwei Li et al.
PHARMACOLOGICAL RESEARCH (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Zhe Lv et al.
SCIENCE (2020)
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert L. Hoffman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase
Mark Andrew White et al.
JOURNAL OF PHYSICAL CHEMISTRY LETTERS (2020)
Structures and distributions of SARS-CoV-2 spike proteins on intact virions
Zunlong Ke et al.
NATURE (2020)
Architecture of a SARS-CoV-2 mini replication and transcription complex
Liming Yan et al.
NATURE COMMUNICATIONS (2020)
Covid-19: What now for remdesivir?
Jeremy Hsu
BMJ-BRITISH MEDICAL JOURNAL (2020)
ACE2: the molecular doorway to SARS-CoV-2
Miriam Marlene Medina-Enriquez et al.
CELL AND BIOSCIENCE (2020)
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L
Michael Dominic Sacco et al.
SCIENCE ADVANCES (2020)
GS-5734: a potentially approved drug by FDA against SARS-Cov-2
Zhonglei Wang et al.
NEW JOURNAL OF CHEMISTRY (2020)
Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis
Laura K. McMullan et al.
LANCET INFECTIOUS DISEASES (2019)
Cepharanthine: An update of its mode of action, pharmacological properties and medical applications
Christian Bailly
PHYTOMEDICINE (2019)
Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
Dong Eon Kim et al.
BIOMOLECULES (2019)
Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus
Egor P. Tchesnokov et al.
SCIENTIFIC REPORTS (2018)
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Late Ebola virus relapse causing meningoencephalitis: a case report
Michael Jacobs et al.
LANCET (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Quantification of 2′-deoxy-2′-β-fluoro-4′-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies
Youmei Peng et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2014)
Synthesis of new 2′-deoxy-2′-fluoro-4′-azido nucleoside analogues as potent anti-HIV agents
Qiang Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Design, Synthesis, and Antiviral Activity of 4′-Azidocytidine Analogues against Hepatitis C Virus Replication: The Discovery of 4′-Azidoarabinocytidine
David B. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The Design, Synthesis, and Antiviral Activity of Monofluoro and Difluoro Analogues of 4′-Azidocytidine against Hepatitis C Virus Replication: The Discovery of 4′-Azido-2′-deoxy-2′-fluorocytidine and 4′-Azido-2′-dideoxy-2′,2′-difluorocytidine
David B. Smith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-α-hydroxyl groups
Klaus Klumpp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication:: The discovery of R1479
David B. Smith et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture
K Klumpp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Design of wide-spectrum inhibitors targeting coronavirus main proteases
HT Yang et al.
PLOS BIOLOGY (2005)
The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor
HT Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)